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In the setting of high salt intake, aldosterone stimulates fibrosis
in the heart, great vessels, and kidney of rats. We used
uninephrectomized rats treated with angiotensin II and placed
on a high salt diet to exaggerate renal fibrosis. We then tested
whether mineralocorticoid receptor blockade by spironolactone
or aldosterone synthase inhibition by FAD286 have similar
effects on end-organ damage and gene expression. Individually,
both drugs prevented the hypertensive response to
uninephrectomy and high salt intake but not when angiotensin
II was administered. Following 4 weeks of treatment with
FAD286, plasma aldosterone was reduced, whereas
spironolactone increased aldosterone at 8 weeks of treatment.
Angiotensin II and high salt treatment caused albuminuria,
azotemia, renovascular hypertrophy, glomerular injury,
increased plasminogen activator inhibitor-1 (PAI-1), and
osteopontin mRNA expression, as well as tubulointerstitial
fibrosis in the kidney. Both drugs prevented these renal effects
and attenuated cardiac and aortic medial hypertrophy while
reducing osteopontin and transforming growth factor-b mRNA
expression in the aorta. The two drugs also reduced cardiac
interstitial fibrosis but had no effect on that of the perivascular
region. Although spironolactone enhanced angiotensin II and
salt-stimulated PAI-1 mRNA expression in aorta and heart,
spironolactone and FAD286 prevented renal PAI-1 mRNA
protein expression. Our study shows that mineralocorticoid
receptor antagonism and aldosterone synthase inhibition
similarly decrease hypertrophy and interstitial fibrosis of the
kidney and heart caused by angiotensin II and high salt.
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published online 18 February 2009
KEYWORDS: aldosterone; mineralocorticoid receptor; plasminogen activator
inhibitor-1
Recent studies highlight the important contribution of
aldosterone to cardiovascular and renal morbidity and
mortality. In rats, in the setting of high salt intake,
aldosterone activates NFkB and stimulates an inflammatory
response followed by fibrosis in the heart, great vessels, and
kidney.1–6 Conversely, mineralocorticoid receptor (MR)
antagonism reduces angiotensin II (Ang II)-induced activa-
tion of NF-kB, oxidative stress, inflammation and cardiac
fibrosis, aortic remodeling, and renal injury in many
models.1,7–10 Clinical studies confirm the relevance of these
findings in humans. During chronic therapy with an
angiotensin-converting enzyme inhibitor or an angiotensin
receptor blocker, aldosterone concentrations can ‘escape’ to
pretreatment levels.11 MR antagonism decreases markers of
myocardial remodeling and mortality in congestive heart
failure,12,13 and decreases albuminuria in diabetic and
hypertensive nephropathy.14
MR activation by corticosterone or by transactivation by
the AT1 receptor may contribute to end-organ damage, and
aldosterone may also act through MR-independent
effects.15–19 The availability of the pharmacological aldoster-
one synthase inhibitor, FAD286, provides a tool to examine
the role of endogenous aldosterone without blocking the MR.
Fiebeler and co-workers20 report that treatment with FAD286
or adrenalectomy significantly reduced mortality, cardiac
hypertrophy, albuminuria, and cardiac and renal inflamma-
tion in rats doubly transgenic for the human renin and
angiotensinogen genes. In this study, we tested the hypothesis
that MR antagonism and aldosterone synthase inhibition
have similar effects on end-organ damage and gene
expression in Ang II/salt-treated rats.
RESULTS
Blood pressure, RAAS parameters, electrolytes and renal
function
Table 1 shows the mean systolic blood pressure (SBP) in each
treatment group measured biweekly by tail-cuff plethysmo-
graphy over the 8-week study period. SBP was significantly
increased by uninephrectomy/salt or by uninephrectomy and
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Ang II/salt administration. Spironolactone or FAD286
reduced SBP following uninephrectomy alone, but neither
drug lowered blood pressure during Ang II infusion. SBP was
measured at least twice by indwelling carotid artery catheter
in a small number of animals in each group between 2 and 5
weeks of therapy, and showed a similar pattern to tail-cuff
plethysmography: sham (N¼ 3) 118.9±9.3 mm Hg, unine-
phrectomy/salt (N¼ 2) 146.3±8.2 mm Hg, uninephrectomy/
salt±spironolactone (N¼ 5) 132.5±9.0 mm Hg, unine-
phrectomy/saltþ FAD286 (N¼ 4) 128.9±15.6 mm Hg, un-
inephrectomy±Ang II/salt (N¼ 4) 147.5±11.3 mm Hg,
uninephrectomyþAng II/saltþ spironolactone (N¼ 4)
140.8±13.0 mm Hg, and uninephrectomyþAng II/salt-
FAD286 (N¼ 3) 146.0±10.9 mm Hg.
Serum potassium concentrations and urinary sodium and
potassium excretion were similar among Ang II/salt-treated
groups (Table 1). Ang II/salt significantly increased serum
blood urea nitrogen and urine albumin excretion. Treatment
with either spironolactone or FAD286 attenuated this effect.
As illustrated in Table 2, Ang II/salt treatment significantly
increased circulating aldosterone concentrations at 4 weeks.
FAD286, but not spironolactone, prevented this effect. In
contrast, at 8 weeks, plasma aldosterone was increased only in
the uninephrectomyþAng II/saltþ spironolactone group.
Corticosterone concentrations were similar among treatment
groups at 4 weeks. Although corticosterone concentrations
were higher in the uninephrectomyþ FAD286 group at 8
weeks, corticosterone concentrations were not different
among the Ang II/salt-treated groups. Circulating active
plasminogen activator inhibitor-1 (PAI-1) antigen concen-
trations were increased in the uninephrectomyþAng II/
saltþ spironolactone group at 4 weeks, whereas by 8 weeks,
PAI-1 concentrations were increased only in the unine-
phrectomyþAng II/salt group.
Tissue morphology and histology
Uninephrectomy caused significant hypertrophy of the
remaining kidney during high salt intake, and there was no
effect of spironolactone or FAD286 on this response
(Figure 1). Ang II infusion caused a further increase in
kidney weight. Spironolactone or FAD286 significantly and
equivalently prevented Ang II/salt-induced renal hypertrophy.
Ang II/salt infusion induced glomerulosclerosis, tubulointer-
stitial fibrosis, and renal artery hypertrophy. Either spirono-
lactone or FAD286 prevented these effects, and there was no
difference in the degree of glomerulosclerosis, tubulointer-
stitial fibrosis, or renal artery hypertrophy in spironolactone-
versus FAD286-treated rats.
Uninephrectomy and high salt alone did not affect heart-
to-body weight ratio. Ang II/salt caused cardiac hypertrophy,
Table 1 | Effect of treatment on systolic blood pressure, electrolytes, and renal function
Sham
(n=5)
Uninephrectomy
(n=7)
Uninephrectomy+
spironolactone (n=6)
Uninephrectomy+
FAD286
(n=6)
Uninephrectomy+
Ang II
(n=7)
Uninephrectomy+
Ang II+spironolactone
(n=6)
Uninephrectomy+
Ang II+FAD286
(n=7)
SBP (mm Hg) 157.7±2.7 168.0±2.4* 159.1±2.2 162.9±2.5 172.2±2.5* 171.7±2.5* 167.4±2.4*
Serum Na+(mmol/l) 137.3±0.5 (N=4) 138.4±1.1 137.6±2.2 (N=5) 138.2±2.6 138.7±2.2 140.8±3.6*,z (N=4) 138.3±1.3 (N=4)
Serum K+(mmol/l) 5.6±0.6 5.1±0.2 5.9±0.3w 5.5±0.3 5.3±0.3 5.40±.2 5.5±0.1
pH 7.47±0.03 (N=4) 7.43±0.04 (N=4) 7.46±0.05 (N=5) 7.42±0.07 (N=5) 7.44±0.07 (N=6) 7.44±0.03 (N=3) 7.38±0.06*z (N=6)
HCO3 26.6±2.2 (N=4) 28.8±2.9 (N=4) 28.0±1.6 (N=4) 26.9±2.5 (N=4) 27.1±1.6 (N=4) 27.7±0.3 (N=4) 27.0±2.7 (N=4)
BUN (mg/100 ml) 22.5±2.1 24.9±2.0 26.6±1.1 26.2±1.9 46.7±8.0*,w,z,y,||,z 23.8±0.9 30.8±0.6
Urine K+ (mmol/l) 132±29 92±25 72±14 80±18 58±14 67±18 95±23
Urine Na+ (mmol/l) 245±44 221±31 269±23 243±49 205±66 214±83 275±115
Urine volume (ml) 22.2±4.8 45.6±17.2* 48.0±4.0* 47.0±10.6* 56.0±11.0* 48.8±14.3* 53.3±38.2*
Urine Na+/K+ 2.0±0.2 3.1±0.4 4.3±0.6* 3.4±0.4 4.2±1.8* 3.7±1.0* 4.1±2.2*
Urine albumin/Cr (mg/mg) 460±226 1027±407 314±114 1062±488 3583±1606* 2621±1074 2537±1694
Ang II, angiotensin II; Bun, blood urea nitrogen; SBP, systolic blood pressure.
*Po0.05 versus sham, wPo0.05 versus uninephrectomy, zPo0.05 versus uninephrectomy+spironolactone, yPo0.05 versus uninephrectomy+FAD286, ||Po0.05 versus
uninephrectomy+Ang II+spironolactone, zPo0.05 versus uninephrectomy+Ang II+FAD286.
Table 2 | Effect of treatment on aldosterone, corticosterone, and plasminogen activator inhibitor-1
Sham
(n=4)
Uninephrectomy
(n=7)
Uninephrectomy+
spironolactone (n=6)
Uninephrectomy+
FAD286 (n=6)
Uninephrectomy+
Ang II (n=6)
Uninephrectomy+Ang II
+spironolactone (n=6)
Uninephrectomy+Ang II
+FAD286 (n=7)
Aldosterone (pg/ml)
4 weeks 208±75 168±40 142±18 131±36 472±159*,w,z,y,|| 374±160z,y 139±10
8 weeks 185±50 151±41 89±23 101±19 229±68 305±135z,y,|| 121±41
Corticosterone (ng/ml)
4 weeks 444±49 506±86 468±35 436±79 504±83 453±45 447±52
8 weeks 289±96 313±51 231±45 389±30z,|| 287±60 299±59 228±40
PAI-1 (ng/ml)
4 weeks 0.8±0.2 0.6±0.3 0.4±0.1 0.6±0.1 1.2±0.4 2.7±1.0*,w,z,y,||,z 0.7±0.1
8 weeks 0.9±0.2 0.8±0.3 0.2±0.0 0.4±0.1 4.0±2.9z,y,# 0.5±0.1 0.7±0.3
*Po0.05 versus sham, wPo0.05 versus uninephrectomy, zPo0.05 versus uninephrectomy+spironolactone, yPo0.05 versus uninephrectomy+FAD286, ||Po0.05 versus
uninephrectomy+Ang II+FAD286, zPo0.05 versus uninephrectomy+Ang II, #Po0.05 versus uninephrectomy+Ang II+spironolactone.
Kidney International (2009) 75, 936–944 937
WB Lea et al.: MR blockade vs aldosterone synthase inhibition o r i g i n a l a r t i c l e
which was prevented by both spironolactone and FAD286
(Figure 2a). In the heart, Ang II/salt induced interstitial
fibrosis, which was more pronounced in the subendocardial
regions and perivascular fibrosis (Figure 2b–f). Either
spironolactone or FAD286 prevented the development of
interstitial fibrosis. Neither drug significantly decreased Ang
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Figure 1 | Effect of treatment on kidney injury. Effect of treatment on (a) kidney weight, (b) glomerular sclerosis, (c) tubulointerstitial
fibrosis, and (d) renal vascular modeling. For post hoc comparisons, *Po0.01 versus sham, wPo0.05 versus uninephrectomy (Neph), zPo0.05
versus uninephrectomyþ spironolactone (SPL), yPo0.05 versus uninephrectomyþ FAD286, ||Po0.05 versus uninephrectomyþAng
IIþ spironolactone, zPo0.05 versus uninephrectomyþAng IIþ FAD286. Masson’s trichrome (original magnification  100) of the kidney in
(e) control, (f) Ang II/salt-treated, (g) Ang II/saltþ spironolactone-treated, and (h) Ang II/saltþ FAD286-treated. The asterisks in (f) denote
areas of tubulointerstitial fibrosis.
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II/salt-stimulated perivascular fibrosis; however, FAD286
reduced Ang II/salt-induced perivascular fibrosis compared
with spironolactone (Figure 2c).
Ang II/salt caused aortic medial thickening, which was
prevented during treatment with spironolactone or FAD286
(medial area 10,629±819, 9667±908, and 7749±981 mm2 in
Ang II/salt, Ang II/saltþ spironolactone, and Ang II/salt-
FAD286, respectively; Po0.05 for Ang II/salt versus all other
groups). Adventitial thickness was statistically similar among
the treatment groups.
Expression of profibrotic genes
In the kidney, Ang II/salt increased osteopontin and PAI-1
mRNA expression, and tended to increase tumor growth
factor-b (Figure 3). Either spironolactone or FAD286
decreased Ang II/salt-stimulated osteopontin and PAI-1
mRNA expression in the kidney. Ang II/salt increased
osteopontin and tumor growth factor-b expression in the
aorta (Figure 3), and spironolactone or FAD286 prevented
these effects. In the heart, Ang II/salt significantly increased
PAI-1 expression. However, during chronic Ang II/salt
treatment, spironolactone enhanced PAI-1 mRNA expression
in the heart and aorta and tumor growth factor-b1 mRNA
expression in the heart. Cardiac PAI-1 mRNA expression
correlated with the perivascular fibrosis score (r¼ 0.362,
P¼ 0.023). By in situ hybridization PAI-1 mRNA expression
localized predominantly to the vasculature of the heart and to
the aortic adventitia (not shown). By western blot, PAI-1
protein was increased 10% in the heart of Ang II/salt-treated
mice (Po0.001 versus nephrectomy alone), but not in the
heart of Ang II/saltþ spironolactone or Ang II/saltþ FAD286
mice. By immunohistochemistry, PAI-1 staining in the
myocytes and vascular smooth muscle cells (VSMCs) was
significantly increased in Ang II/salt-treated animals
(P¼ 0.04) but there was no difference among Ang II/salt,
Ang II/saltþ spironolactone, and Ang II/saltþ FAD286
(average score 2.1±0.9, 3.1±0.9, 3.6±1.5, and 3.5±0.6 in
uninephrectomy alone, uninephrectomyþAng II/salt, unin-
ephrectomyþAng II/saltþ spironolactone, and uninephrec-
tomyþAng II/saltþ FAD, respectively).
Effect of spironolactone on Ang II and aldosterone-induced
PAI-1 mRNA expression in VSMCs in vitro
Aldosterone (106 M) increased PAI-1 mRNA expression and
enhanced the effect of Ang II (106 M) on PAI-1 expression in
cultured rat VSMCs (Figure 4). Spironolactone (106 M)
prevented Ang II-stimulated PAI-1 mRNA expression and
attenuated the effect of Ang IIþ aldosterone on PAI-1
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Figure 2 | Effect of treatment on cardiac injury. Effect of treatment on (a) heart weight, (b) cardiac interstitial fibrosis, and (c) perivascular
adventitial fibrosis. For post hoc comparisons, *Po0.01 versus sham, wPo0.05 versus uninephrectomy (Neph), zPo0.05 versus
uninephrectomyþ spironolactone (SPL), yPo0.05 versus uninephrectomyþ FAD286, ||Po0.05 versus uninephrectomyþAng
IIþ spironolactone, zPo0.05 versus uninephrectomyþAng IIþ FAD286. (d) Focal area of subendocardial interstitial and perivascular fibrosis
in heart from Ang II-treated rat (Masson’s trichrome, original magnification  100). Persistent perivascular fibrosis in Ang II/salt-treated rats
receiving (e) spironolactone ( 400) and (f) FAD286. The asterisks in (d) denote cardiac interstitial fibrosis; arrowhead denotes perivascular/
periadventitial fibrosis.
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expression such that the PAI-1 mRNA expression was similar
to that after treatment with aldosterone alone but still
increased compared with control. Spironolactone had no
effect on aldosterone-induced PAI-1 expression.
DISCUSSION
This study compared two different pharmacological strategies
for negating the effect of aldosterone on Ang II/salt-induced
end-organ damage–MR antagonism and aldosterone synthase
inhibition. We hypothesized that MR antagonism would have
a greater effect on Ang II/salt-induced end-organ damage if
Ang II activated the MR through an aldosterone-independent
mechanism. Conversely, we hypothesized that aldosterone
synthase inhibition would have a greater effect on Ang II/salt-
induced end-organ damage if aldosterone contributed to
damage through an MR-independent mechanism. As
reported earlier in separate studies of spironolactone and
FAD286,1,6,7,9,10,20,21 however, both agents prevented Ang II/
PAI-1 kidney Osteopontin
kidney
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Figure 3 | Effect of treatment on expression of PAI-1, osteopontin, and tumor growth factor b (TGF-b) mRNA in the kidney, heart,
and aorta. For post hoc comparisons, *Po0.05 versus sham, wPo0.01 versus uninephrectomy (Neph), zPo0.01 versus uninephrectomyþ
spironolactone (SPL), yPo0.01 versus uninephrectomyþ FAD286, ||Po0.01 versus uninephrectomyþAng IIþ spironolactone, zPo0.01
versus uninephrectomyþAng IIþ FAD286, #Po0.01 versus uninephrectomyþAng II.
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salt-induced renal injury, cardiac and aortic hypertrophy, and
cardiac interstitial fibrosis through a blood pressure-inde-
pendent mechanism. Neither spironolactone nor FAD286
prevented Ang II/salt-induced perivascular fibrosis at the
doses administered.
Numerous earlier studies of MR antagonism have
established that spironolactone or eplerenone decreases
cardiac hypertrophy and interstitial fibrosis, aortic medial
thickening, renal hypertrophy, tubulointerstitial fibrosis, and
glomerular injury, as in this study.1,6,7,9,10,21 Likewise,
Fiebeler et al.20 showed earlier that FAD286 decreased
aldosterone concentrations, cardiac hypertrophy, albuminur-
ia, and tubulointerstitial fibrosis in doubly transgenic rats
overexpressing the human renin and angiotensin genes
(dTGR). The authors did not report any effect of FAD286
on cardiac fibrosis or aortic remodeling in that study.
Minnaard-Huiban et al. 22 have also reported that FAD286A,
the R(þ )-enantiomer fadrozole, and the MR antagonist
canrenoate similarly reversed preexisting cardiac fibrosis in
spontaneously hypertensive heart failure rats. To the best of
our knowledge, however, this study is the first to compare the
effects of pharmacological MR antagonism and aldosterone
synthase inhibition on renal injury. Both spironolactone and
FAD286 prevented Ang II/salt-induced albuminuria and
glomerular injury. The equivalent effects of spironolactone
and FAD286 on Ang II/salt-induced renal injury, cardiac
interstitial fibrosis, and cardiac and aortic hypertrophy
suggest that endogenous aldosterone induces these effects
through an MR-dependent mechanism.
In contrast to the effect of spironolactone and FAD286 on
cardiac hypertrophy and interstitial fibrosis, neither drug
attenuated Ang II/salt-induced perivascular fibrosis in the
heart at the doses studied. The effect of FAD286 on
perivascular fibrosis has not been reported earlier. The lack
of effect of spironolactone on perivascular coronary fibrosis,
in contrast to interstitial fibrosis, may relate to dose. MR
antagonism reduces perivascular fibrosis in the Ang II/salt
model in part through a blood pressure-dependent mechan-
ism. For example, Neves et al 10 reported that, in contrast to
the MR-dependent effect of spironolactone on cardiac
interstitial fibrosis, blood pressure reduction with either
spironolactone or hydralazine decreased perivascular fibrosis
in Ang II/salt-treated rats.
We administered spironolactone at a dose of 5.8 mg/kg per d,
whereas many earlier studies of the effect of spironolactone
on cardiac fibrosis utilized doses of 20–30 mg/kg per d or
higher. We chose this lower dose to avoid an antihypertensive
effect. Earlier studies indicate that acute doses of spirono-
lactone as low as 3 mg/kg inhibit aldosterone binding in
tissue in vivo and that chronic doses of 4–5.8 mg/kg per d
spironolactone decrease cardiac fibrosis or improve vascular
function.23,24 In addition, the peak plasma concentration of
spironolactone measured after administration of 5 mg/kg in
the rat (560 ng/ml)25 is 8-fold higher than the peak plasma
concentration (80 ng/ml) reported in humans after admin-
istration of 100 mg spironolactone. Importantly, the observa-
tion that spironolactone increased serum aldosterone
concentrations at 8 weeks in Ang II/salt-treated rats and that
spironolactone prevented Ang II/salt-induced cardiac hyper-
trophy and interstitial fibrosis, as well as renal injury,
indicates that systemic MR blockade was achieved.
The lack of effect of spironolactone on cardiac perivas-
cular fibrosis in Ang II/salt-treated rats could result from
MR-independent effects of aldosterone. In this regard,
Danser and co-workers have reported that aldosterone
enhances Ang II-mediated coronary vasoconstriction
through protein kinase C and extracellular signal-regulated
kinase 1/2-dependent, but MR-independent, pathways.26 It is
interesting to note that although spironolactone enhanced
the effect of Ang II/salt on circulating aldosterone concen-
trations in this study, a beneficial effect of spironolactone on
cardiac perivascular fibrosis in other studies has been
associated with decreased or unchanged plasma or urinary
aldosterone concentrations.1,8,27 Alternatively, non-specific
effects of spironolactone, such as calcium channel blockade,
could have contributed to the differential effects of
spironolactone and FAD286.28,29
Spironolactone and FAD286 attenuated osteopontin
mRNA expression in the kidneys and aortae of Ang II/salt-
treated rats, in agreement with earlier studies indicating that
aldosterone increases osteopontin expression through an
MR-dependent mechanism.6,21 Likewise, both spironolactone
and FAD286 decreased renal PAI-1 expression, just as
aldosterone has been shown earlier to increase, and
spironolactone to decrease, PAI-1 expression in the kid-
ney.30–32 FAD286 also decreased PAI-1 mRNA expression in
the heart in Ang II/salt-treated rats consistent with the data
indicating that exogenous aldosterone increases PAI-1
expression in the heart in vivo.32 Spironolactone enhanced
Ang II/salt-stimulated PAI-1 mRNA expression in the aorta
and heart. Increased aldosterone at 8 weeks in Ang II/
saltþ spironolactone-treated rats may have contributed to
this effect on aortic and cardiac mRNA expression. On the
other hand, circulating PAI-1 antigen was increased at 4
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Figure 4 | Effect of spironolactone (SPL, 1 lM) on PAI-1
expression in rat vascular smooth muscle cells treated with
angiotensin II (Ang II, 1 lM), aldosterone (aldo, 1 lM) or the
combination. *Po0.05 versus vehicle, wPo0.05 versus Ang II
alone, zPo0.05 versus spironolactone, yPo0.05 versus aldoþ
Ang II.
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weeks and not 8 weeks during Ang II/saltþ spironolactone.
Moreover, both spironolactone and FAD286 prevented the
stimulatory effect of Ang II on PAI-1 protein expression in
the heart, consistent with an earlier report of an inhibitory
effect of spironolactone on cardiac PAI-1 expression in
Ang II/L-NAME (NG-nitro-L-arginine methyl ester)-treated
mice.33
To explore the possibility that ambient aldosterone
concentrations influence the effect of MR blockade on Ang
II/salt-stimulated PAI-1 mRNA expression in the vasculature,
we examined the effect of high dose spironolactone on PAI-1
expression in cultured VSMCs. We chose to study the effect of
spironolactone in VSMCs due to the vascular localization of
cardiac PAI-1 expression by in situ hybridization, and because
the effect of spironolactone on Ang II-stimulated PAI-1
expression has not been reported in this cell type. Ang II alone
increased PAI-1 expression. Consistent with earlier studies
showing that Ang II can activate the MR,16,34 spironolactone
attenuated Ang II-stimulated PAI-1 expression suggesting that
Ang II increases PAI-1 expression through an MR-dependent
mechanism in VSMCs. In contrast, aldosterone increased PAI-
1 expression through an MR-independent mechanism. The
data suggest that in vivo, chronically elevated aldosterone
concentrations contribute to increased perivascular PAI-1
mRNA expression during concurrent treatment with Ang II/
salt and spironolactone.
In summary, activation of the renin–angiotensin–aldoster-
one system (RAAS) promotes cardiovascular and renal
injury. Aldosterone may act through MR-independent effects,
whereas MR activation by ligands other than aldosterone may
contribute to end-organ damage. Data from this study
indicate that during high salt intake and chronic elevation
of Ang II, endogenous aldosterone and MR activation
promote renal hypertrophy, glomerulosclerosis, tubulointer-
stitial fibrosis, vascular remodeling, and profibrotic gene
expression in the kidney. Endogenous aldosterone also
contributes to cardiac and aortic hypertrophy and cardiac
interstitial fibrosis through the MR, whereas neither MR
antagonism nor aldosterone synthase inhibition decreased
perivascular fibrosis at the doses administered. MR antagon-
ism and aldosterone synthase inhibition have similar
protective effects.
MATERIALS AND METHODS
Rats
Male Sprague–Dawley rats (Harlan Sprague–Dawley, Indianapolis,
IN, USA) were housed in a temperature-controlled facility with a
fixed light–dark cycle. All protocols and animal procedures were
approved by the Vanderbilt University Institutional Animal Care
and Use Committee.
Experimental protocol
Eight-week-old rats were randomized to one of seven treatment
groups: (1) sham-operated control rats provided 1% NaCl in the
drinking water, vehicle by osmotic mini-pump (Alzet, Alza Corp.,
Palo Alto, CA, USA) and placebo chow; (2) uninephrectomized
control rats given 1% NaCl, vehicle and placebo chow; (3)
uninephrectomized rats given 1% NaCl, vehicle and spironolactone
chow; (4) uninephrectomized control rats given 1% NaCl, vehicle,
and FAD286 chow; (5) uninephrectomized rats given 1% NaCl, Ang
II (1 mg/h) by mini-pump, and vehicle chow; (6) uninephrectomized
rats given 1% NaCl, Ang II, and spironolactone chow; and (7)
uninephrectomized rats given 1% NaCl, Ang II, and FAD286 chow.
Drugs were formulated in standard rodent chow by TestDiet
(Richmond, IN, USA) at concentrations calculated to provide doses
of 5.8 mg/kg/d spironolactone and 4 mg/kg/d FAD286 HCl salt,
based on studies published earlier indicating that these doses
decreased end-organ damage.20,23
At randomization, uninephrectomy and mini-pump implanta-
tion were performed under isoflurane anesthesia. Pumps were
explanted and replaced under anesthesia at 4 weeks. Blood pressure
was measured before randomization and at every 2 weeks for 8
weeks using tail-cuff plethysmography (BP-2000 Blood Pressure
Analysis System, Visitech Systems, Apex, NC, USA) in unanesthe-
tized, trained rats pre-warmed for 30 min at 37 1C. In addition,
carotid artery catheters were initially inserted for direct arterial
blood pressure measurements at the time of pump implantation in a
subset of animals within each group, but not in all rats, due to
difficulty maintaining catheter patency. Blood (400 ml) was collected
via the saphenous vein under isoflurane anesthesia before rando-
mization and at 4 and 8 weeks. Fifty microliters of blood was
collected directly into an iSTAT EC8þ cartridge (Heska Corp.,
Loveland, CO, USA) for determination of blood chemistries. The
remaining blood was collected into chilled EDTA-coated capillary
tubes (Microvette CB K2E, Sarstedt AG & Co., Numbrecht,
Germany), centrifuged immediately at 6000 rpm for 5 min and
plasma was stored at 80 1C. For PAI-1 concentrations, blood was
collected into acidified citrate. Rats were housed in individual
metabolic cages (Nalgene, Braintree Scientific, Braintree, MA, USA)
at 0, 4, and 8 weeks for 24-h urine collection.
Animals were euthanized with pentobarbital and blood was
collected through cardiac puncture. The renal artery was clamped
and blood was drawn from the right ventricle. The base of the heart,
the descending aorta, the adrenal glands, sections of kidney and
liver, were fixed in 4% buffered paraformaldehyde overnight, and
then processed and embedded in paraffin for histological evaluation.
The remaining heart, aorta, kidney and liver, were snap frozen in
liquid nitrogen for mRNA analysis.
Laboratory assays
Serum sodium, potassium, chloride, pH, HCO3, and blood urea
nitrogen were measured by ion-selective electrode potentiometry.
Blood urea nitrogen was first hydrolyzed to ammonium by the
enzyme urease. Urine albumin was determined using an immuno-
turbidimetric assay for albumin and colorimetric assay for creatinine
(DCA2000RþAnalyzer and Microalbumin/creatinine cartridges,
Bayer Corp., Ekhart, IN, USA). Urine sodium and potassium were
measured by flame photometry. Plasma aldosterone was measured
using a commercially available radioimmunoassay (MP Biomedi-
cals, Irvine, CA, USA), a primary antibody to aldosterone (NIDDK
National Hormone and Peptide Program, Torrance, CA, USA), and
a secondary anti-rabbit gamma globulin antibody (Linco Research,
St Charles, MO, USA). Plasma corticosterone was measured using a
commercially available radioimmunoassay kit (ImmuChem Double
Antibody Corticosterone Kit, MP Biomedicals, Irvine, CA, USA).
Active PAI-1 antigen was measured using a two-site ELISA method
(ZYMUTEST, RK003A, DiaPharma, West Chester, OH, USA).
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Histopathological analysis
Investigators unaware of treatment assignment assessed morphol-
ogy. To evaluate left ventricular free wall thickness, and aortic
adventitial and medial thickness, Masson’s trichrome-stained aortic
and cardiac cross-sections were photographed on a Zeiss AxioScop
40 using MRGrab 1.0. and analyzed using ImageJ software (NIH,
UK). Cardiac and renal interstitial fibrosis were scored from 0 to 4,
with 0 indicating no fibrosis, 1 indicating 0–10%, 2 indicating
10–25%, 3 indicating 26–50%, and 4 indicating 51–75% involvement
of tissue by fibrosis. Coronary arteries were graded as normal (0), or
as showing mild perivascular fibrosis (1), hypertrophy with fibrosis
and some collagen within the media (2), or extensive hypertrophy
and perivascular fibrosis with periadvential mononuclear cell
infiltrate (3). Renal arteries were graded as normal (0), or as
showing mild (1), moderate (2), or severe hypertrophy (3).
Glomerular sclerosis was graded on a scale of 0 to 4, with 0
indicating normal, 1 indicating 1–10% of glomeruli involved with
sclerosis, 2 indicating 19–25% of glomeruli involved, 3 indicating
26–50%, and 4 indicating 450% of glomeruli sclerosed. PAI-1
immunohistochemistry was performed on heart and aortae.
Staining of myocytes, VSMCs, and vascular endothelium was
graded as no staining (0), trace/focal staining (1þ ), mild/focal
staining (2þ ), or diffuse staining (3þ ). Immunohistochemistry
and in situ hybridization were performed as described earlier.35
Quantitative real-time reverse transcriptase polymerase
chain reaction
Total cardiac RNA was extracted using RNAWiz (Ambion, Austin,
TX, USA) and Rneasy Midi Kit (Qiagen, Valencia, CA, USA). Total
aortic and kidney RNA were extracted using Rneasy Mini Kit
(Qiagen). Reverse transcription was performed using TaqMan
Reverse Transcription Kit (Applied Biosystems, Branchburg, NJ,
USA). Quantitative real-time polymerase chain reaction was
performed on the iCycler iQ Multi-Color Real-Time PCR Detection
System (BioRad, Hercules, CA, USA) using iQ SYBR Green
Supermix (Biorad). Primers used were: PAI-1 (forward (TCCAC
AAGTCTGATGGTAGC), reverse (GTTGCTCTTCCATTGTCTGA));
osteopontin (forward (CCAGCACACAAGCAGACGTT), reverse
(TCAGTCCATAAGCCAAGCTATCAC)); tumor growth factor-b
(forward (CGTGGAAATCAATGGGATCAG), reverse (GGCCATG
AGGAGCAGGAA)); and glyceraldehyde-3-phosphate dehydrogen-
ase (forward (CCTGCCAAGTATGATGACATCAA), reverse (AGCC
CAGGATGCCCTTTAGT)). Experimental cycle threshold (Ct)
values were normalized to glyceraldehyde-3-phosphate dehydro-
genase measured on the same plate, and fold differences in gene
expression were determined using the 2DDCt method.
Western blotting for PAI-1
Western blotting was performed as described earlier.36 The sample
protein (125 mg) was loaded and separated by 10% sodium dodecyl
sulfate-polyacrylamide gel electrophoresis and transferred into a 0.2-
mm nitrocellulose membrane. PAI-1 was detected with a specific
rabbit anti-mouse PAI-1 polyclonal antibody (Santa Cruz Biotech-
nology, Santa Cruz, CA, USA) at 1:500 dilution.
Measurement of PAI-1mRNA expression in cultured rat
vascular smooth muscle cells
Vascular smooth muscle cells were isolated from aortic explants
from Wistar-Kyoto rats (Charles River Laboratories, Wilmington,
MA, USA) and cultured in low glucose Dulbecco’s modified Eagle’s
medium containing 10% fetal bovine serum (Invitrogen, Carlsbad,
CA, USA) and 1.0% penicillin and streptomycin, as described
earlier.37 After 24 h, cells were treated with vehicle, Ang II, or
aldosterone, in the presence or absence of spironolactone. The final
concentration of all active reagents was 106 M. Stock solutions of
reagents (104 M) containing 1.4% ethanol and 0.1% dimethylsulf-
oxide were prepared and diluted 1:100 for each experiment. Media
containing the same concentrations of ethanol and dimethylsulf-
oxide was used as control. Twenty-four hours later, complementary
DNA was isolated using uMacs One-Step cDNA kit (Miltenyi Biotec
Inc., Auburn, CA, USA). PAI-1 mRNA expression was measured by
reverse transcriptase-PCR as described above.
Statistics
Data are presented as means±s.e. of the mean. The effect of
treatment on SBP was determined using repeated-measures General
Linear Model, in which the within-subject variable was time and the
between-subject variable was treatment. Comparisons of hormone
concentrations, injury scores, and tissue expression were made using
one-way ANOVA (analysis of variance). Results were confirmed
using non-parametric methods. A P-value of o0.05 was considered
significant.
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